查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1950525

肽类药物偶联物CDMO服务市场：按营运规模、服务产品、胜肽类型、治疗领域和最终用户划分，全球预测，2026-2032年

Peptide-Drug Conjugates CDMO Service Market by Scale Of Operation, Service Offering, Peptide Type, Therapeutic Area, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年肽类药物偶联物 CDMO 服务市值为 3.4567 亿美元，预计到 2026 年将增长至 3.5795 亿美元，预计到 2032 年将达到 4.8021 亿美元，复合年增长率为 4.80%。

关键市场统计数据
基准年 2025 3.4567亿美元
预计年份：2026年 3.5795亿美元
预测年份 2032 4.8021亿美元
复合年增长率 (%) 4.80%

全面概述胜肽类药物偶联物CDMO服务，重点介绍其技术深度、营运准备以及对开发商的战略价值驱动因素。

肽类药物偶联物 (PDC) 的 CDMO 行业概况需要一份重点突出、清晰阐述当前能力、价值提案以及面向製药和生物技术相关人员的战略重点的概要。本执行摘要首先重点介绍 CDMO 合作伙伴如何实现复杂的有效载荷-连接子-肽整合，以及从肽合成到偶联、製剂和分析表征的一体化服务为何对缩短临床开发週期和提高产品品质至关重要。

连接子化学、胜肽合成、分析自动化和监管要求的创新如何从根本上重塑CDMO伙伴关係模式

近期发生的变革性变化正在重塑胜肽-药物偶联物的研发、生产和临床应用方式。连接子化学和可裂解设计方面的进步提高了偶联物的治疗精准度，迫使合约研发生产机构（CDMO）采用专门的偶联平台和更严格的分析控制。同时，胜肽合成调查方法的改进，包括固相和液相化学的最佳化，正在缩短合成週期，降低杂质含量，并促进药物研发团队与生产合作伙伴之间更紧密的合作。

评估 2025 年关税如何促使 CDMO 重组其采购业务、考虑近岸外包并加强其供应链韧性。

2025年美国关税的累积影响已对胜肽类药物偶联物生态系统中合约研发生产机构（CDMO）的营运和供应链经济造成了显着压力。依赖进口的投入品，例如特种试剂、某些层析法树脂和分析仪器零件，其到岸成本均增加，迫使契约製造及其客户重新评估筹资策略和供应商选择标准。海关合规方面的行政复杂性和物流交货前置作业时间的变化进一步加剧了这些投入成本压力，迫使营运团队采用更动态的库存管理和采购惯例。

将治疗需求、开发规模、服务能力、胜肽化学类型和最终用户期望与CDMO选择标准连结起来的详细細項分析

全面的細項分析揭示了不同治疗领域、企业规模、服务产品、胜肽类型和最终用户类别在服务需求和技术期望方面的细微差异。从治疗领域来看，开发人员主要关注以下几个方面：心血管领域，细分为动脉粥样硬化和心臟衰竭，并具有特定的药物动力学和稳定性要求；免疫学领域，涵盖自体免疫疾病和发炎性疾病，重点在于降低免疫抗原性；传染病感染疾病，涵盖细菌和病毒感染疾病，製剂和递送固态肿瘤骨髓恶性肿瘤影响偶联物的标靶化；

比较和评估区域监管成熟度、製造能力和供应链韧性，以塑造跨区域CDMO服务采购。

区域趋势对胜肽类药物偶联物价值链上的服务可用性、监管参与和成本结构均有显着影响。在美洲，强大的临床试验生态系统和大型製药企业聚集地为先进的生产能力和监管经验提供了支撑，而物流基础设施和密集的供应商网络则有助于快速扩大生产规模和建立临床供应体系。儘管对本地生产能力和人才培养的过渡性投资持续增强该地区的韧性，但成本压力和关税因素正在影响企业选择采购特殊投入品的地点。

CDMO企业的定位和伙伴关係趋势揭示了其在能力投资、策略性收购和人才主导竞争优势方面的努力。

胜肽类药物偶联物CDMO领域的竞争动态呈现出策略定位的频谱，从垂直整合型供应商到高度专业化的利基市场参与者，不一而足。领先的服务供应商透过投资平台技术来降低偶联异质性，透过强大的分析套件提供深入的表征能力，并透过连接药物发现和生产的製程开发团队来实现差异化。同时，小规模的专业公司则透过提供敏捷性、客製化的开发路径和紧密的合作模式来参与竞争，从而加快新型偶联物首次人体给药的进程。

针对CDMO和申办方，可采取具有重大影响的营运和策略步骤，以增强偶联物专案的可生产性、监管准备和供应链韧性。

产业领导者应采取一系列切实可行的措施，增强自身韧性，加速创新，并在胜肽类药物偶联物的研发和生产领域中获得战略优势。优先投资于模组化、灵活的生产平台，以实现从发现阶段合成到临床和商业化生产的快速过渡，从而降低技术风险并加速临床试验进程。同时，应拓展内部分析能力和自动化表征工作流程，以确保杂质谱分析和批次间可比性。这将简化与监管机构的沟通，并有助于加快核准。

结合专家访谈、文献综述、监管框架分析和情境压力测试的系统性调查方法，能够提供实际的见解。

本执行摘要的调查方法结合了定性和定量方法，以确保获得可靠的三角验证结果。主要研究包括对高级研发主管、采购专业人员、生产主管以及直接管理胜肽类药物偶联物专案的偶联化学和分析开发专家进行结构化访谈和有针对性的讨论。这有助于深入了解不同治疗领域和研发阶段所面临的技术挑战、伙伴关係标准和营运限制。

整合技术、业务和策略考量，指导CDMO合作决策，并推动偶联疗法的成功研发。

总之，胜肽类药物偶联物（PDC）CDMO环境正处于技术复杂性不断提高和商业性压力不断演变的双重挑战之下。偶联化学和胜肽合成技术的进步提高了生产合作伙伴的技术门槛，而贸易动态的变化和区域投资趋势正在重塑筹资策略。这些因素共同造就了这样一个市场格局：技术专长、监管能力和供应链韧性将决定伙伴关係的成败。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 胜肽类药物偶联物CDMO服务市场（依营运规模划分）

  • 临床阶段
    • 第一阶段
    • 第二阶段
    • 第三阶段
  • 商业的
    • 大规模生产
    • 小规模生产
  • 药物发现阶段
  • 飞行员

9. 胜肽类药物偶联物CDMO服务市场（依服务类型划分）

  • 分析服务
    • 特征描述
    • 发布测试
    • 稳定性测试
  • 加入
    • 可裂解连接子
    • 不可切割的连接子
  • 配方
    • 液体
    • 冷冻干燥
  • 胜肽合成
    • 液相
    • 固相
  • 製程开发
    • 下游工艺
    • 上游工程

10. 依胜肽类型分類的胜肽类药物偶联物CDMO服务市场

  • 圆
  • 线性类型
  • 合格类型
  • 胜肽类似物

11. 肽类药物偶联物CDMO服务市场（依治疗领域划分）

  • 循环系统
    • 动脉粥状硬化
    • 心臟衰竭
  • 免疫学
    • 自体免疫疾病
    • 发炎性疾病
  • 感染疾病
    • 细菌感染疾病
    • 病毒感染疾病
  • 肿瘤学
    • 骨髓恶性肿瘤
    • 固态肿瘤

12. 依最终用户分類的胜肽类药物偶联物CDMO服务市场

  • 学术机构
  • 生物技术
  • 合约研究机构
  • 政府
  • 製药公司

13. 肽类药物偶联物CDMO服务市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

14. 胜肽类药物偶联物CDMO服务市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国肽类药物偶联物CDMO服务市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国胜肽类药物偶联物CDMO服务市场

17. 中国：胜肽类药物偶联物CDMO服务市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Aobious, Inc.
  • Asymchem, Inc.
  • Bachem Holding AG
  • BioDuro, Inc.
  • Biopeptek, Inc.
  • Bio-Synthesis Inc.
  • BOC Sciences Ltd.
  • Catalent, Inc.
  • CordenPharma International GmbH
  • Creative Peptides, Inc.
  • Evotec SE
  • GenScript Biotech Corporation
  • JPT Peptide Technologies GmbH
  • Lonza Group AG
  • Peptide International, Inc.
  • Piramal Pharma Solutions
  • Polypeptide Group GmbH
  • Recipharm AB
  • ScinoPharm Taiwan Ltd.
  • SN Biopharm Co., Ltd.
  • Thermo Fisher Scientific Inc.
  • USV Private Limited
  • WuXi AppTec Co., Ltd.
  • Xinbang Pharma Co., Ltd.
Product Code: MRR-4F7A6D4FD8BC

The Peptide-Drug Conjugates CDMO Service Market was valued at USD 345.67 million in 2025 and is projected to grow to USD 357.95 million in 2026, with a CAGR of 4.80%, reaching USD 480.21 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 345.67 million
Estimated Year [2026] USD 357.95 million
Forecast Year [2032] USD 480.21 million
CAGR (%) 4.80%

Comprehensive orientation to peptide-drug conjugates CDMO services highlighting technical depth, operational readiness, and strategic value drivers for developers

The peptide-drug conjugates CDMO landscape requires a focused introduction that frames current capabilities, value propositions, and strategic priorities for stakeholders across pharmaceutical and biotechnology sectors. This executive summary initiates the narrative by clarifying how CDMO partners enable complex payload-linker-peptide integrations and why integrated service offerings from peptide synthesis through conjugation, formulation, and analytical characterization matter for accelerating clinical timelines and enhancing product quality.

By situating CDMO capabilities against the evolving technical demands of conjugate design, this section highlights the practical intersections between scientific rigor and operational execution. It underscores the importance of end-to-end process control, risk-managed supply chains, and flexible manufacturing paradigms that allow developers to translate discovery-stage sequences into clinical-grade materials. This orientation sets expectations for the subsequent analysis and positions readers to evaluate CDMO selection criteria through the lenses of technical competence, regulatory readiness, and commercial scalability.

How innovations in linker chemistry, peptide synthesis, analytical automation, and regulatory expectations are fundamentally reshaping CDMO partnership models

The recent period has produced transformative shifts that reshape how peptide-drug conjugates are developed, manufactured, and brought to clinic. Advances in linker chemistry and cleavable designs have increased the therapeutic precision of conjugates, prompting CDMOs to incorporate specialized conjugation platforms and tighter analytical controls. Concurrently, improvements in peptide synthesis methodologies, including optimized solid-phase and liquid-phase chemistries, have shortened synthesis cycles and reduced impurity profiles, encouraging closer collaboration between discovery teams and manufacturing partners.

Moreover, data-driven integration and automation have permeated analytical workflows, enabling higher-throughput characterization and more reliable stability assessments. Regulatory expectations have evolved in parallel, with agencies emphasizing robust characterization of conjugation heterogeneity, impurity control strategies, and reagent traceability. As a result, CDMOs are shifting from purely transactional service providers to strategic partners offering process development, regulatory support, and lifecycle management. Finally, the industry's risk management posture has matured; developers increasingly prioritize supply chain resilience and multi-sourcing strategies, which drives demand for geographically diversified manufacturing footprints and stronger contractual alignment between innovators and service providers.

Assessing how 2025 tariff measures prompted procurement realignment, nearshoring considerations, and increased supply chain resilience efforts in CDMO operations

The cumulative impact of United States tariff measures enacted in 2025 has exerted measurable pressure on CDMO operations and supply chain economics across the peptide-drug conjugate ecosystem. Import-dependent inputs such as specialized reagents, certain chromatography resins, and analytic instrumentation components experienced increased landed costs, prompting contract manufacturers and their clients to reassess procurement strategies and supplier selection criteria. These input cost pressures were compounded by administrative complexity in customs compliance and shifts in logistical lead times, which required operational teams to adopt more dynamic inventory and procurement practices.

In response, many organizations accelerated supplier qualification programs in alternative jurisdictions and pursued renegotiated supplier contracts to stabilize pricing and availability. Nearshoring and regional capacity expansion became more attractive where tariff differentials threatened margins or schedule certainty, and some CDMOs prioritized in-house vertical capabilities to reduce exposure to tariff-sensitive external vendors. Importantly, the tariff environment pushed cross-functional teams to enhance scenario planning, stress-test supply chains, and incorporate tariff contingency clauses into master service agreements, thereby improving resilience and clarifying cost pass-through mechanisms between service providers and sponsors.

Granular segmentation analysis linking therapeutic needs, development scale, service capabilities, peptide chemotypes, and end-user expectations to CDMO selection criteria

A careful segmentation lens reveals nuanced service requirements and technical expectations across therapeutic areas, scale of operation, service offering, peptide type, and end-user categories. When viewed through the therapeutic area dimension, developers focus on Cardiovascular applications that break down into Atherosclerosis and Heart Failure needs with specific pharmacokinetic and stability demands; Immunology priorities that span Autoimmune Diseases and Inflammatory Disorders with emphasis on immunogenicity mitigation; Infectious Disease vectors that cover Bacterial Infection and Viral Infection where formulation and delivery concerns influence conjugate design; and Oncology indications that span Hematological Malignancies and Solid Tumors requiring tailored payload potency and tumor-targeting strategies.

Considering scale of operation, clinical development stages impose different CDMO expectations: Discovery and preclinical research demand rapid iterative synthesis and agile conjugation workflows; early-phase Clinical work across Phase I through Phase III requires scalable process development and stringent analytical release testing; Pilot runs test manufacturability and process robustness; and Commercial production focuses on reproducible large-scale manufacturing while also accommodating small-scale specialized batches. In terms of service offering, comprehensive engagements typically integrate peptide synthesis-whether via liquid-phase or solid-phase techniques-conjugation methods utilizing cleavable or noncleavable linkers, formulation approaches that select between liquid and lyophilized formats, process development spanning upstream and downstream operations, and detailed analytical services covering characterization, release testing, and stability testing. The peptide type under consideration-cyclic, linear, modified, or peptidomimetics-influences synthetic route complexity, impurity profiles, and conjugation site selection, thereby shaping the selection of CDMOs with relevant technical experience. Finally, end users range from academic groups and biotechnology firms to contract research organizations, government entities, and pharmaceutical companies; each cohort presents distinct procurement cycles, risk tolerances, and collaboration models that CDMOs must address through tailored service agreements and client engagement frameworks.

Comparative regional evaluation of regulatory maturity, manufacturing capacity, and supply chain resilience shaping CDMO service sourcing across geographies

Regional dynamics materially affect service availability, regulatory interactions, and cost structures across the peptide-drug conjugate value chain. In the Americas, strong clinical trial ecosystems and a concentration of large pharmaceutical sponsors support advanced manufacturing capabilities and regulatory experience, while logistics infrastructure and a dense supplier base enable responsive scale-up and fast clinical supply deployment. Transitional investments in local capacity and workforce development continue to strengthen regional resilience, although cost pressures and tariff considerations influence where sponsors elect to source specialized inputs.

The Europe, Middle East & Africa landscape blends mature regulatory frameworks in Western Europe with emerging manufacturing clusters in select EMEA hubs; firms operating here benefit from established analytical standards and cross-border talent pools, yet they must navigate heterogeneous regulatory pathways and variable reimbursement contexts. In Asia-Pacific, the combination of rapid manufacturing capacity expansion, increasingly sophisticated biotech sectors, and competitive cost structures positions the region as a critical source of both commodity and specialized CDMO services. However, clients must weigh regional regulatory differences, intellectual property considerations, and quality oversight mechanisms when selecting partners. Across regions, the interplay of regulatory expectations, supply chain resilience, and cost structures determines how sponsors and CDMOs prioritize investment and operational partnerships.

Corporate positioning and partnership dynamics among CDMOs revealing capability investments, strategic acquisitions, and talent-driven competitive advantages

Competitive dynamics among companies in the peptide-drug conjugate CDMO space reveal a spectrum of strategic positioning from vertically integrated providers to highly specialized niche players. Leading service providers differentiate through investments in platform technologies that reduce conjugation heterogeneity, robust analytical suites that provide deep characterization capabilities, and process development teams that bridge discovery and manufacturing. At the same time, smaller specialist firms compete by offering agility, bespoke development pathways, and close collaborative models that can accelerate first-in-human timelines for novel conjugates.

Partnership activity has intensified as sponsors seek to de-risk development paths and secure capacity. M&A and strategic alliances frequently target capabilities such as advanced peptide synthesis platforms, enhanced conjugation chemistries, or in-house analytics that address specific regulatory challenges. Talent acquisition remains a differentiator, with companies that cultivate cross-disciplinary expertise-combining synthetic chemistry, conjugation science, and bioprocess engineering-better positioned to respond to complex client needs. Finally, operational excellence in quality systems, regulatory submissions support, and supply chain transparency informs buyer choice and underpins long-term commercial relationships.

High-impact operational and strategic steps for CDMOs and sponsors to enhance manufacturability, regulatory readiness, and supply chain resilience in conjugate programs

Industry leaders should adopt a set of actionable measures to strengthen resilience, accelerate innovation, and capture strategic advantage in peptide-drug conjugates development and manufacturing. Prioritize investment in modular and flexible manufacturing platforms that allow rapid transitions between discovery-scale synthesis and clinical or commercial production, thereby reducing technical risk and shortening go-to-clinic timelines. Simultaneously, expand in-house analytical capabilities and automated characterization workflows to ensure robust impurity profiling and batch-to-batch comparability, which simplifies regulatory interactions and supports expedited approvals.

Furthermore, implement diversified supplier strategies and regional redundancy for tariff-sensitive inputs to guard against geopolitical and trade disruptions. Establish collaborative R&D models with sponsors that embed process development teams early in the discovery phase to enable manufacturability-by-design approaches. Strengthen contractual frameworks to include clear provisions for contingency sourcing, cost pass-through, and shared risk during capacity constraints. Finally, invest in workforce development programs that create cross-functional teams capable of integrating peptide chemistry, conjugation science, and downstream processing, together with data infrastructure that supports knowledge capture, predictive analytics, and continuous improvement initiatives.

Methodical research approach combining expert interviews, literature synthesis, regulatory mapping, and scenario-based stress testing to deliver actionable insights

The research methodology underpinning this executive summary combined qualitative and quantitative approaches to ensure robust, triangulated insights. Primary research comprised structured interviews and targeted discussions with senior R&D leaders, procurement professionals, and manufacturing executives who directly manage peptide-drug conjugate programs, together with subject-matter experts in conjugation chemistry and analytical development. These engagements provided contextual understanding of technical pain points, partnership criteria, and operational constraints observed across therapeutic areas and development stages.

Secondary research involved systematic review of scientific literature, regulatory guidance, patent landscapes, and publicly available corporate disclosures to map technological trajectories and regulatory expectations. Data synthesis employed cross-validation techniques to reconcile practitioner perspectives with documented precedents and technical performance indicators. The analysis also incorporated scenario-based stress testing-examining tariff impacts, supply chain disruptions, and capacity constraints-to inform resilience recommendations. Quality control included peer review by domain experts and consistency checks to ensure clarity, reproducibility, and actionable relevance for decision-makers.

Synthesis of technical, operational, and strategic imperatives guiding CDMO engagement decisions and enabling reliable advancement of conjugate therapeutics

In conclusion, the peptide-drug conjugate CDMO landscape stands at the intersection of deepening technical complexity and evolving commercial pressures. Advances in conjugation chemistry and peptide synthesis have elevated the technical bar for manufacturing partners, while shifting trade dynamics and regional investments have reshaped sourcing strategies. Together, these forces drive a market environment where technical competence, regulatory acumen, and supply chain resilience determine successful partnerships.

Decision-makers should integrate the segmentation, regional, and operational insights presented here to align CDMO selection and investment strategies with program-specific needs. By proactively addressing manufacturing scalability, analytical depth, and contractual clarity, sponsors and service providers can reduce development risk and improve the likelihood of timely clinical progression. The path forward favors collaborative models that integrate early process development, diversify supply options, and continuously invest in capabilities that translate scientific promise into reliable, compliant therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Peptide-Drug Conjugates CDMO Service Market, by Scale Of Operation

  • 8.1. Clinical
    • 8.1.1. Phase I
    • 8.1.2. Phase II
    • 8.1.3. Phase III
  • 8.2. Commercial
    • 8.2.1. Large Scale Manufacturing
    • 8.2.2. Small Scale Manufacturing
  • 8.3. Discovery
  • 8.4. Pilot

9. Peptide-Drug Conjugates CDMO Service Market, by Service Offering

  • 9.1. Analytical Services
    • 9.1.1. Characterization
    • 9.1.2. Release Testing
    • 9.1.3. Stability Testing
  • 9.2. Conjugation
    • 9.2.1. Cleavable Linkers
    • 9.2.2. Noncleavable Linkers
  • 9.3. Formulation
    • 9.3.1. Liquid
    • 9.3.2. Lyophilized
  • 9.4. Peptide Synthesis
    • 9.4.1. Liquid Phase
    • 9.4.2. Solid Phase
  • 9.5. Process Development
    • 9.5.1. Downstream
    • 9.5.2. Upstream

10. Peptide-Drug Conjugates CDMO Service Market, by Peptide Type

  • 10.1. Cyclic
  • 10.2. Linear
  • 10.3. Modified
  • 10.4. Peptidomimetics

11. Peptide-Drug Conjugates CDMO Service Market, by Therapeutic Area

  • 11.1. Cardiovascular
    • 11.1.1. Atherosclerosis
    • 11.1.2. Heart Failure
  • 11.2. Immunology
    • 11.2.1. Autoimmune Diseases
    • 11.2.2. Inflammatory Disorders
  • 11.3. Infectious Disease
    • 11.3.1. Bacterial Infection
    • 11.3.2. Viral Infection
  • 11.4. Oncology
    • 11.4.1. Hematological Malignancies
    • 11.4.2. Solid Tumors

12. Peptide-Drug Conjugates CDMO Service Market, by End User

  • 12.1. Academic
  • 12.2. Biotechnology
  • 12.3. Contract Research Organization
  • 12.4. Government
  • 12.5. Pharmaceutical

13. Peptide-Drug Conjugates CDMO Service Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Peptide-Drug Conjugates CDMO Service Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Peptide-Drug Conjugates CDMO Service Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Peptide-Drug Conjugates CDMO Service Market

17. China Peptide-Drug Conjugates CDMO Service Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Aobious, Inc.
  • 18.6. Asymchem, Inc.
  • 18.7. Bachem Holding AG
  • 18.8. BioDuro, Inc.
  • 18.9. Biopeptek, Inc.
  • 18.10. Bio-Synthesis Inc.
  • 18.11. BOC Sciences Ltd.
  • 18.12. Catalent, Inc.
  • 18.13. CordenPharma International GmbH
  • 18.14. Creative Peptides, Inc.
  • 18.15. Evotec SE
  • 18.16. GenScript Biotech Corporation
  • 18.17. JPT Peptide Technologies GmbH
  • 18.18. Lonza Group AG
  • 18.19. Peptide International, Inc.
  • 18.20. Piramal Pharma Solutions
  • 18.21. Polypeptide Group GmbH
  • 18.22. Recipharm AB
  • 18.23. ScinoPharm Taiwan Ltd.
  • 18.24. SN Biopharm Co., Ltd.
  • 18.25. Thermo Fisher Scientific Inc.
  • 18.26. USV Private Limited
  • 18.27. WuXi AppTec Co., Ltd.
  • 18.28. Xinbang Pharma Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SCALE OF OPERATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SERVICE OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLINICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLINICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COMMERCIAL, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY LARGE SCALE MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY LARGE SCALE MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY LARGE SCALE MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SMALL SCALE MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SMALL SCALE MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SMALL SCALE MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PILOT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PILOT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PILOT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CHARACTERIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CHARACTERIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CHARACTERIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY RELEASE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY RELEASE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY RELEASE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY STABILITY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY STABILITY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY STABILITY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONJUGATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONJUGATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONJUGATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONJUGATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLEAVABLE LINKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLEAVABLE LINKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLEAVABLE LINKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY NONCLEAVABLE LINKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY NONCLEAVABLE LINKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY NONCLEAVABLE LINKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY FORMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY FORMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY FORMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY LYOPHILIZED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY LYOPHILIZED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY LYOPHILIZED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY LIQUID PHASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY LIQUID PHASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY LIQUID PHASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SOLID PHASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SOLID PHASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SOLID PHASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY DOWNSTREAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY DOWNSTREAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY DOWNSTREAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY UPSTREAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY UPSTREAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY UPSTREAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CYCLIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CYCLIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CYCLIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY LINEAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY LINEAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY LINEAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY MODIFIED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY MODIFIED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY MODIFIED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDOMIMETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDOMIMETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDOMIMETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ATHEROSCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ATHEROSCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ATHEROSCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY IMMUNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY IMMUNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFLAMMATORY DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFLAMMATORY DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFLAMMATORY DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY BACTERIAL INFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY BACTERIAL INFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY BACTERIAL INFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY VIRAL INFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY VIRAL INFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY VIRAL INFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ACADEMIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ACADEMIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ACADEMIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY BIOTECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY BIOTECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY BIOTECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY GOVERNMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY GOVERNMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY GOVERNMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COMMERCIAL, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONJUGATION, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COMMERCIAL, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONJUGATION, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COMMERCIAL, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONJUGATION, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COMMERCIAL, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONJUGATION, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COMMERCIAL, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONJUGATION, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 244. MIDDLE EAST PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COMMERCIAL, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONJUGATION, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 258. MIDDLE EAST PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 260. AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 261. AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 262. AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COMMERCIAL, 2018-2032 (USD MILLION)
  • TABLE 263. AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONJUGATION, 2018-2032 (USD MILLION)
  • TABLE 266. AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 267. AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 268. AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 269. AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 271. AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 272. AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 273. AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 274. AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 275. AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC PEPTIDE-DRUG CONJUGATES CDMO SERVICE MA